--- title: "Upper Limb Essential Tremor M25-850 | Sutter Health" description: "A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Treatment of Upper Limb Essential Tremor in Adults" url: "https://www.sutterhealth.org/research/clinical-trials/upper-limb-essential-tremor-m25-850-2099129041" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Clinical trials](https://www.sutterhealth.org/research/clinical-trials) / 4. Upper Limb Essential Tremor M25-850 # Upper Limb Essential Tremor M25-850 **Status:** Coming Soon #### Study details View study details on [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07673107). #### Locations - Sacramento #### Clinical trial FAQs Information for patients and study volunteers, including [frequently asked questions](https://www.sutterhealth.org/research/faqs). A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Treatment of Upper Limb Essential Tremor in Adults ![Nicklesh Thakur, D.O.](https://dyn.mktgcdn.com/p/zos6e_ZdN1G6JIcS4P4FiRUyMPCwgfowfbIm1F2O5f4/fit=crop,gravity=auto,dpr=2,width=188,height=250,quality=100) Nicklesh Thakur, D.O. Principal investigator [View profile](https://www.sutterhealth.org/research/investigators/nicklesh-thakur-do-1049681045) ## Sub-Investigator [Steven W Nakano, M.D.](https://www.sutterhealth.org/research/investigators/steven-w-nakano-md-2057362163) ## Related clinical trials [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) - Clinical trial ### [Acute Ischemic Stroke PICASSO](https://www.sutterhealth.org/research/clinical-trials/acute-ischemic-stroke-picasso-1094825919) Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial **Status:** Open to Enrollment - Clinical trial ### [ALS Healey Platform Trial Master Protocol](https://www.sutterhealth.org/research/clinical-trials/als-healey-platform-trial-master-protocol-2057369170) HEALEY ALS Platform Trial **Status:** Closed to Enrollment - Clinical trial ### [ALS SPG302 Expanded Access Protocol](https://www.sutterhealth.org/research/clinical-trials/als-spg302-expanded-access-protocol-2036968358) Intermediate-size Patient Population Expanded Access Protocol for SPG302 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) **Status:** Open to Enrollment - Clinical trial ### [Amyotrophic Lateral Sclerosis (ALS) C302-CLN-2301](https://www.sutterhealth.org/research/clinical-trials/amyotrophic-lateral-sclerosis-als-c302-cln-2301-2044044761) Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study With Additional 24-Week Blinded Active Extension to Evaluate the Safety and Efficacy of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) **Status:** Open to Enrollment - Clinical trial ### [Amyotrophic Lateral Sclerosis (ALS) PL101-ALS301 PREVAILS](https://www.sutterhealth.org/research/clinical-trials/amyotrophic-lateral-sclerosis-als-pl101-als301-prevails-2064309735) A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants With Amyotrophic Lateral Sclerosis **Status:** Open to Enrollment [View all clinical trials](https://www.sutterhealth.org/research-search-results?verticalKey=clinical_trial) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/clinical-trials/upper-limb-essential-tremor-m25-850-2099129041#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Clinical trials","item":"https://www.sutterhealth.org/research/clinical-trials"},{"@type":"ListItem","position":4,"name":"Upper Limb Essential Tremor M25-850"}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalWebPage","@id":"https://www.sutterhealth.org/research/clinical-trials/upper-limb-essential-tremor-m25-850-2099129041#medicalwebpage","name":"Upper Limb Essential Tremor M25-850","description":"A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Treatment of Upper Limb Essential Tremor in Adults","url":"https://www.sutterhealth.org/research/clinical-trials/upper-limb-essential-tremor-m25-850-2099129041","inLanguage":"en-US","dateModified":"2026-10-29","publisher":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"},"medicalAudience":{"@type":"MedicalAudience","audienceType":"Patient"},"mainEntity":{"@id":"https://www.sutterhealth.org/research/clinical-trials/upper-limb-essential-tremor-m25-850-2099129041#medicaltrial"},"breadcrumb":{"@id":"https://www.sutterhealth.org/research/clinical-trials/upper-limb-essential-tremor-m25-850-2099129041#breadcrumblist"},"mentions":[{"@type":"Person","name":"Nicklesh Thakur, D.O.","url":"https://www.sutterhealth.org/research/investigators/nicklesh-thakur-do-1049681045","jobTitle":"Principal Investigator","affiliation":{"@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org"}}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalTrial","@id":"https://www.sutterhealth.org/research/clinical-trials/upper-limb-essential-tremor-m25-850-2099129041#medicaltrial","name":"Upper Limb Essential Tremor M25-850","alternateName":"A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Treatment of Upper Limb Essential Tremor in Adults","url":"https://www.sutterhealth.org/research/clinical-trials/upper-limb-essential-tremor-m25-850-2099129041","description":"A Phase 2b Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Treatment of Upper Limb Essential Tremor in Adults","identifier":"NCT07673107","code":{"@type":"MedicalCode","codeValue":"NCT07673107","codingSystem":"ClinicalTrials.gov"},"sameAs":"https://clinicaltrials.gov/study/NCT07673107","status":"https://schema.org/NotYetRecruiting","healthCondition":[{"@type":"MedicalCondition","name":"Upper Limb Essential Tremor"}],"studyLocation":[{"@type":"AdministrativeArea","name":"Sacramento"}]} ```